Net Margin
Adynxx Inc

-2 244.1%
Current
-723%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 244.1%
=
Net Income
-10.3m
/
Revenue
460k

Net Margin Across Competitors

No Stocks Found

Adynxx Inc
Glance View

Market Cap
580.8 USD
Industry
Biotechnology

Adynxx, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 6 full-time employees. The firm is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.

ADYX Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 244.1%
=
Net Income
-10.3m
/
Revenue
460k
What is the Net Margin of Adynxx Inc?

Based on Adynxx Inc's most recent financial statements, the company has Net Margin of -2 244.1%.

Back to Top